Rick Schnellman
Oprichter bij Rediscovery Life Sciences LLC
Profiel
Rick Schnellman is the founder of Rediscovery Life Sciences LLC.
He currently holds the position of Chief Scientific Officer & Director at Rediscovery Life Sciences AKI LLC and Director at Mitochem Therapeutics, Inc.
Actieve functies van Rick Schnellman
Bedrijven | Functie | Begin |
---|---|---|
Rediscovery Life Sciences AKI LLC
Rediscovery Life Sciences AKI LLC Medical/Nursing ServicesHealth Services Rediscovery Life Sciences AKI LLC engages in the development of treatments with less risk through drug repurposing. The company is headquartered in Charleston, SC. | Hoofd Techniek/Wetenschap/O&O | - |
Rediscovery Life Sciences LLC
Rediscovery Life Sciences LLC BiotechnologyHealth Technology Rediscovery Life Sciences LLC operates as a clinical-stage biotechnology company that focuses to develop suramin in acute kidney injury. The company was founded by Rick Schnellman and is headquartered in Charleston, SC. | Oprichter | - |
Mitochem Therapeutics, Inc.
Mitochem Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Mitochem Therapeutics, Inc. is a privately held company based in Charleston, SC that develops therapies for diseases involving mitochondrial dysfunction. Mitochem Therapeutics has a proprietary library of mitochondrial protective compounds, and early proof of concept in numerous in vivo models for retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The lead compound MC16 is a first-in-class small molecule that up-regulates pro-survival and anti-oxidant pathways. In 2021, the Food and Drug Administration (FDA) granted orphan drug designation status to MC16 for the treatment of RP. The company is pursuing partnerships to develop non-ophthalmic indications such as Parkinson's, Alzheimer's, ALS, muscular dystrophies, diabetes, ischemias, and kidney diseases. The company was founded by Bärbel Rohrer and Craig C. Beeson to develop a new approach to treating neurodegeneration and aging diseases by protecting mitochondrial homeostasis. The CEO is Michael Voevodsky. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
Rediscovery Life Sciences AKI LLC
Rediscovery Life Sciences AKI LLC Medical/Nursing ServicesHealth Services Rediscovery Life Sciences AKI LLC engages in the development of treatments with less risk through drug repurposing. The company is headquartered in Charleston, SC. | Health Services |
Rediscovery Life Sciences LLC
Rediscovery Life Sciences LLC BiotechnologyHealth Technology Rediscovery Life Sciences LLC operates as a clinical-stage biotechnology company that focuses to develop suramin in acute kidney injury. The company was founded by Rick Schnellman and is headquartered in Charleston, SC. | Health Technology |
Mitochem Therapeutics, Inc.
Mitochem Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Mitochem Therapeutics, Inc. is a privately held company based in Charleston, SC that develops therapies for diseases involving mitochondrial dysfunction. Mitochem Therapeutics has a proprietary library of mitochondrial protective compounds, and early proof of concept in numerous in vivo models for retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The lead compound MC16 is a first-in-class small molecule that up-regulates pro-survival and anti-oxidant pathways. In 2021, the Food and Drug Administration (FDA) granted orphan drug designation status to MC16 for the treatment of RP. The company is pursuing partnerships to develop non-ophthalmic indications such as Parkinson's, Alzheimer's, ALS, muscular dystrophies, diabetes, ischemias, and kidney diseases. The company was founded by Bärbel Rohrer and Craig C. Beeson to develop a new approach to treating neurodegeneration and aging diseases by protecting mitochondrial homeostasis. The CEO is Michael Voevodsky. | Health Technology |